| Status: Excluded due to NICE appraisal | |
Product meets AWMSG criteria due to NICE appraisal TA863: Somatrogon for treating growth disturbance in children and young people aged 3 and over |
|
Medicine details |
|
| Medicine name | somatrogon (Ngenla®) |
| Formulation | 24 mg , 60 mg solution for injection |
| Reference number | 3764 |
| Indication | Treatment of children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone |
| Company | Pfizer Ltd |
| BNF chapter | Endocrine system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/07/2022 |
| NICE guidance | TA863: Somatrogon for treating growth disturbance in children and young people aged 3 and over |